GSK grabs $1.25B cash and a cut of Gilead­'s megablock­buster Bik­tarvy sales as HIV ri­vals set­tle patent suit

Three years af­ter Vi­iV Health­care, the HIV spe­cial­ist ma­jor­i­ty owned by Glax­o­SmithK­line, first sued Gilead over al­leged patent in­fringe­ment on one of its top drugs, the two com­pa­nies have set­tled the case.

Gilead will pay Vi­iV $1.25 bil­lion in cash — while agree­ing to set aside a 3% roy­al­ty on all US sales of Bik­tarvy un­til Oc­to­ber 2027.

A megablock­buster triplet ther­a­py giv­en as a dai­ly pill, Bik­tarvy brought in $6.09 bil­lion from the US alone in 2020. By 2027, Jef­feries an­a­lysts es­ti­mate that cu­mu­la­tive US sales would reach about $50 bil­lion — trans­lat­ing to about $2 bil­lion in to­tal roy­al­ties for Vi­iV.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN